Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Upfront admixing antibodies and EGFR inhibitors preempts sequential treatments in lung cancer models

Abstract Some antibacterial therapies entail sequential treatments with different antibiotics, but whether this approach is optimal for anti‐cancer tyrosine kinase inhibitors (TKIs) remains open. EGFR mutations identify lung cancer patients who can derive benefit from TKIs, but most patients develop...

Full description

Bibliographic Details
Main Authors: Ilaria Marrocco, Donatella Romaniello, Itay Vaknin, Diana Drago‐Garcia, Roni Oren, Mary Luz Uribe, Nishanth Belugali Nataraj, Soma Ghosh, Raya Eilam, Tomer‐Meir Salame, Moshit Lindzen, Yosef Yarden
Format: Article
Language:English
Published: Wiley 2021-04-01
Series:EMBO Molecular Medicine
Subjects:
EGFR TKIs
first‐line therapy
mAbs
NSCLC
resistance
Online Access:https://doi.org/10.15252/emmm.202013144

Internet

https://doi.org/10.15252/emmm.202013144

Similar Items